Ijaz S Jamall
Dr. Jamall is President and Principal Scientist with Risk-Based Decisions, Inc. He has worked on the development and implementation of quantitative risk assessment methodologies for use in drug development and evaluation, and as a toxicologist. Dr. Jamall has 25 years of experience in consulting and 35 years of experience in Toxicology. Dr. Jamall has conducted epidemiological studies in the US, Eastern Europe, and in South Asia, notably on occupational and environmental exposures to chemicals and viral pathogens and their attendant risks to human health. Beginning in 2005, Dr. Jamall was involved in evaluating a study to estimate the prevalence of Hepatitis C in South Asia. This led to his involvement in the design of a pilot clinical trial to evaluate the role of antioxidants and cytokines, in conjunction with Interferon and Ribavarin, in the treatment of Chronic Hepatitis C in that region. In January 2007, Dr. Jamall was appointed Research Director (a pro bono position) for the Xeroderma Pigmentosum Family Support Group. Dr. Jamall is a Fellow of the Theodor-Billroth-Academy.